SCHEDULE 13G
 
Amendment No. 0
DENALI THERAPEUTICS INC
COMMON STOCK
Cusip #24823R105
Check the appropriate box to designate the rule pursuant to which this 
Schedule is filed:
[ ] 	  Rule 13d-1(b)
[x] 	  Rule 13d-1(c)
[ ] 	  Rule 13d-1(d)
Cusip #24823R105
Item 1: 	   	Reporting Person - FMR LLC
Item 2: 	   	(a)  	[ ]
   	   	(b)  	[ ]
Item 4: 	   	Delaware
Item 5: 	   	3,077,989
Item 6: 	   	0
Item 7: 	   	8,387,312
Item 8: 	   	0
Item 9: 	   	8,387,312
Item 11: 	   	9.533%
Item 12: 	   	HC
Cusip #24823R105
Item 1: 	   	Reporting Person - Abigail P. Johnson
Item 2: 	   	(a)  	[ ]
   	   	(b)  	[ ]
Item 4: 	   	United States of America
Item 5: 	   	0
Item 6: 	   	0
Item 7: 	   	8,387,312
Item 8: 	   	0
Item 9: 	   	8,387,312
Item 11: 	   	9.533%
Item 12: 	   	IN
 
Item 1(a). 	    	Name of Issuer:
 
  	  	          	DENALI THERAPEUTICS INC
 
Item 1(b). 	    	Address of Issuer's Principal Executive Offices:
 
  	  	          	151 OYSTER POINT BLVD
2ND FLOOR SOUTH
  	  	          	San Francisco, CA 94080
  	  	          	US
 
Item 2(a). 	     	 Name of Person Filing:
 
  	   	               	 FMR LLC
 
Item 2(b). 	     	 Address or Principal Business Office or, if None, 
Residence:
 
  	   	               	 245 Summer Street, Boston, Massachusetts 02210
 
Item 2(c). 	     	 Citizenship:
 
  	   	               	 Not applicable
 
Item 2(d). 	     	 Title of Class of Securities:
 
  	   	               	 COMMON STOCK
 
Item 2(e). 	     	 CUSIP Number:
 
  	   	               	 24823R105
 
Item 3. 	    	Not Applicable
 
Item 4. 	    	Ownership
 
  	  	     	(a)    Amount Beneficially Owned: 	8,387,312
 
  	  	     	(b)    Percent of Class: 	9.533%
 
  	  	     	(c)    Number of shares as to which such person has:
 
  	  	     	       (i)    sole power to vote or to direct the vote: 	
3,077,989
 
  	  	     	       (ii)    shared power to vote or to direct the vote: 	0
 
  	  	     	       (iii)    sole power to dispose or to direct the 
disposition of: 	8,387,312
 
  	  	     	       (iv)    shared power to dispose or to direct the 
disposition of: 	0
 
Item 5. 	    	Ownership of Five Percent or Less of a Class.
 
  	    	     	Not applicable.
 
Item 6. 	    	Ownership of More than Five Percent on Behalf of Another 
Person.
 
  	One or more other persons are known to have the right to receive 
or the power to direct the receipt of dividends from, or the proceeds 
from the sale of, the COMMON STOCK of DENALI THERAPEUTICS INC. No one 
other person's interest in the COMMON STOCK of DENALI THERAPEUTICS INC.
is more than five percent of the total outstanding COMMON STOCK. 
  	 
Item 7. 	    	Identification and Classification of the Subsidiary Which 
Acquired the Security Being Reported on By the Parent Holding Company.
 
  	    	     	See attached Exhibit A.
 
Item 8. 	    	Identification and Classification of Members of the Group.
 
  	    	     	Not applicable.
 
Item 9. 	    	Notice of Dissolution of Group.
 
  	    	  	Not applicable.
 
Item 10. 	    	Certifications.
 
  	    	     	

By signing below I certify that, to the best of my knowledge and belief, 
the securities referred to above were not acquired and are not held for the 
purpose of or with the effect of changing or influencing the control of the 
issuer of the securities and were not acquired and are not held in 
connection with or as a participant in any transaction having that purpose 
or effect.

 
Signature
 
  	    	     	

After reasonable inquiry and to the best of my knowledge and belief, I 
certify that the information set forth in this statement is true, complete 
and correct.

  	December 15, 2017
  	Date
 
  	/s/ Marc R. Bryant
  	Signature
 
  	Marc R. Bryant
  	 Duly authorized under Power of Attorney effective as of September 23, 
2015, by and on behalf of FMR LLC and its direct and indirect subsidiaries*


* This power of attorney is incorporated herein by reference to Exhibit 24 
to the Schedule 13G filed by FMR LLC on June 10, 2016, accession number: 
0000315066-16-005935


Exhibit A
 

                 Pursuant to the instructions in Item 7 of Schedule 13G, 
the following table lists the identity and Item 3 classification, if 
applicable, of each relevant entity that beneficially owns shares of the 
security class being reported on this Schedule 13G.

 
Entity 	ITEM 3 Classification
Fidelity Institutional Asset Management Trust Company 	BK
FMR CO., INC 	IA
IMPRESA MANAGEMENT LLC * 	IA
  	 
  	 
* Entity beneficially owns 5% or greater of the outstanding shares of the 
security class being reported on this Schedule 13G.
 
 

 

                Abigail P. Johnson is a Director, the Chairman and the 
Chief Executive Officer of FMR LLC.

 

                Members of the Johnson family, including Abigail P. 
Johnson, are the predominant owners, directly or through trusts, of Series 
B voting common shares of FMR LLC, representing 49% of the voting power of 
FMR LLC. The Johnson family group and all other Series B shareholders have 
entered into a shareholders' voting agreement under which all Series B 
voting common shares will be voted in accordance with the majority vote of 
Series B voting common shares. Accordingly, through their ownership of 
voting common shares and the execution of the shareholders' voting 
agreement, members of the Johnson family may be deemed, under the 
Investment Company Act of 1940, to form a controlling group with respect to 
FMR LLC.

 

                Neither FMR LLC nor Abigail P. Johnson has the sole power 
to vote or direct the voting of the shares owned directly by the various 
investment companies registered under the Investment Company Act ("Fidelity 
Funds") advised by Fidelity Management & Research Company ("FMR Co"), a 
wholly owned subsidiary of FMR LLC, which power resides with the Fidelity 
Funds' Boards of Trustees. Fidelity Management & Research Company carries 
out the voting of the shares under written guidelines established by the 
Fidelity Funds' Boards of Trustees.

 

                This filing reflects the securities beneficially owned, or 
that may be deemed to be beneficially owned, by FMR LLC, certain of its 
subsidiaries and affiliates, and other companies (collectively, the "FMR 
Reporters"). This filing does not reflect securities, if any, beneficially 
owned by certain other companies whose beneficial ownership of securities 
is disaggregated from that of the FMR Reporters in accordance with 
Securities and Exchange Commission Release No. 34-39538 (January 12, 1998).

 

 

RULE 13d-1(k)(1) AGREEMENT
 

                The undersigned persons, on December 15, 2017, agree and 
consent to the joint filing on their behalf of this Schedule 13G in 
connection with their beneficial ownership of the COMMON STOCK of DENALI 
THERAPEUTICS INC at December 12, 2017.

 
  	FMR LLC
 
  	By /s/ Marc R. Bryant
  	Marc R. Bryant
  	Duly authorized under Power of Attorney effective as of September 23, 
2015, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
 
  	Abigail P. Johnson
 
  	By /s/ Marc R. Bryant
  	Marc R. Bryant
  	Duly authorized under Power of Attorney effective as of December 16, 
2015, by and on behalf of Abigail P. Johnson*


* This power of attorney is incorporated herein by reference to Exhibit 24 
to the Schedule 13G filed by FMR LLC on June 10, 2016, accession number: 
0000315066-16-005935